Characterizing up to 2 years of Ofatumumab onboarding and utilization among real-world relapsing multiple sclerosis patients in Australia - the EAFToS Secondary Use of Data Study

被引：0

作者：

Nelson, Morag ^{[1
]}

Van der Walt, Anneke ^{[2
]}

Broadley, Simon ^{[3
]}

Burton, Jason ^{[4
,5
]}

Hardy, Todd

Kemp, Clare ^{[1
]}

Walker, Rob ^{[1
]}

Berry, Patricia ^{[1
]}

Lam, Lien ^{[1
]}

机构：

[1] Novartis Pharmaceut Australia, Macquarie Pk, Australia

[2] Monash Univ, Cent Clin Sch, Clayton, Vic, Australia

[3] Griffith Univ, Menzies Hlth Inst Queensland, Griffith, NSW, Australia

[4] Nexus Neurol, Murdoch, WA, Australia

[5] Univ Sydney, Concord Hosp, Darlington, Durham, England

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-35

引用

页码：NP17 / NP17

页数：1